Aspirin May Lower the Risk of Prostate Cancer
From the Winter 2014 QUEST NEWSLETTER-a publication of the Urological Research Foundation (URF)
Researchers followed 6,390 men who had a PSA of 2.5-10 ng/mL and a negative biopsy result at the start of the study. Half of the men in the study took aspirin and/or another NSAID. The other half of the men did not take these drugs.
After 4 years, researchers found that men who took aspirin and/or NSAIDs had a 13% lower risk of developing prostate cancer. These men also had a 17% lower risk of developing aggressive prostate cancer.
The researchers did not have data on dose or frequency, which is a limitation of the study. Study author Adriana Vidal, PhD, of Duke University said, “Our data support the hypothesis that anti- inflammatory drugs may have a biological role in arresting prostate cancer development, but this requires formal prospective testing in randomized trials. In the meantime, men should discuss with their doctors the benefits and risks of taking these medicines to potentially lower prostate cancer risk.”
The men in the study were part of the REDUCE trial, sponsored by GlaxoSmithKline. The trial was designed to test whether dutasteride, a drug for enlarged prostate, reduced the risk of prostate cancer.
How Does Aspirin Reduce Cancer Mortality?
Previous studies have suggested that taking aspirin or other NSAIDs—even at a low dose—could reduce the incidences of cancer death and metastasis. These drugs block the enzyme COX-1, which is commonly found in platelets. Blocking COX-1 inhibits the adherence of platelets to cancer cells to prevent metastatis. A recent study at Vanderbilt University found that aspirin also inhibited production of the enzyme COX-2, which reduced levels of prostaglandin E2 (PGE2). PGE2 is a hormone that spurs cancer metastasis.
Research from these studies was presented at the 13th Annual American Association for Cancer Research (AACR) International Conference on Frontiers in Cancer Prevention Research.
About the URF (http://www.drcatalona.com/)
The funds and energies of the Urological Research Foundation (URF) are directed to research for the prevention, detection, treatment and cure of diseases of the prostate and most specifically, prostate cancer.
The mission of the Urological Research Foundation is to support research and patient education in prostate cancer.
Prostate cancer causes the death of tens of thousands of men every year and terrible dysfunction and suffering for additional tens of thousands. The need for more medical progress against this disease is compellingly clear.
The vision, over 20 years ago, which led to the URF and which guides the work of the foundation to this day, is that we must support the energies, efforts and expertise of those who treat prostate cancer and those who are searching for a cure.
The Medical Director of the URF, Dr. William J. Catalona, leads one of America’s premier teams of physicians and scientists in this endeavor. Providing the support to them that would accelerate the progress for both treatment of prostate cancer and the search for a cure is a primary goal of the URF.